The trial obtained both its Most important endpoints, with semaglutide two.4 mg demonstrating statistically significant and exceptional enhancements in liver fibrosis without any worsening of steatohepatitis, along with resolution of steatohepatitis with no worsening of liver fibrosis in individuals with MASH as compared to placebo.1Excretion The m